Gabriel Lopez-Berestein

The University of Texas M.D. Anderson Cancer Center



Gabriel Lopez-Berestein is a Professor in the Department of Experimental Therapeutics at MD Anderson Cancer Center (MDACC) and served as the Executive Director of the MDACC Pharmaceutical Development Center. He is internationally known for his research pertaining to development of nanomedical applications that has resulted in more than 200 patents and clinical trials and the FDA-approved drug, Abelcet™ (liposomal amphotericin-B), which is available worldwide and considered standard treatment for life-threatening fungal infections. For the last 30 years Dr. Lopez-Berestein has been studying different aspects of cell death and differentiation and cell signaling.

Roles at PDDS 2017: Nanoparticle delivery of non-coding RNAs Session Chair